Prenetics Announces Fourth Quarter and Full Year 2022 Financial Results, New Business Strategy Focused on Precision Oncology
LONDON AND HONG KONG, Mar 14, 2023 - (ACN Newswire via SEAPRWire.com) - Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading genomics and precision oncology company, today announced financial results for the fourth quarter and full year ended December 31, 2022.Financial Highlights-- Revenue of US$275.8 million in the full year 2022-- Revenue of US$52.3 million in the fourth quarter 2022-- Adjusted EBITDA of US$58.3 million in the full year 2022-- Adjusted EBITDA of US$12.1 million in the fourth quarter 2022-- Cash and other short-term assets of US$242.1 million as of December 31, 2022Recent Highlights-- Embarked on a new business strategy focused on precision oncology, as the Company exits the COVID-19 testing business.-- Acquired ACT Genomics, the first Asian company to receive FDA clearance for its comprehensive genomic profiling test for solid tumors, a significant milestone for Prenetics in executing its new focus in precision oncology. -- Formed a new Scientific Advisory Board with a diverse group of highly respected experts in precision oncology and genomics, to provide strategic input and guide the further development of Prenetics' cancer genomics...
